Open

Phase 1 Cancer study testing ICVB-1042

The purpose of this study is to test the safety and tolerability of the IV administered drug ICVB-1042 in patients with solid advance tumors

Age & Gender

18 years ~ 99 years
Male, Female

Location

United States (Nationwide)

What will be asked of you

If selected for the study, you will receive the study with the drug through an IV for 5 visits. You will then be followed up by the study team for 2 months.

Incentives

Study Medication

Total length of participation:
3 months

Looking for Specific Volunteers

Able to participate:

You have a solid advanced or metastatic tumor
You had progression of your cancer on at least one prior standard of care therapy
You have a life expectancy of more than 3 months

Not eligible if:

It has been less than 28 days from last Standard of Care treatment
You have had major surgery in the past 28 days
You are pregnant or lactating

Contact the Team

Visit Location

Lineberger Clincal Research

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Sid Sheth
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

23-0298

ClinicalTrials.gov

NCT05904236

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.